pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

803 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • NEJM retracts pivotal data for Amgen's Tavneos
    Pivotal data for Amgen’s Tavneos have been retracted from the New England Journal of Medicine, creating another obstacle for the beleaguered autoimmune drug. Two academic authors requested the re…
    Endpoints · 25d ago↗ source
  • John Reed on J&J’s R&D model, oncology deals and pipeline expansion potential
    John Reed has overseen the pipelines of three of the largest drugmakers since leaving Southern California's Sanford Burnham medical research institute 13 years ago, giving him unique insight into h…
    Endpoints · 25d ago↗ source
  • EU lobby urges member states to improve Europe’s life sciences sector
    More than 200 biopharma investors and firms have signed an open letter calling for European governments to improve Europe’s life sciences sector. The Friday letter was addressed to EU member stat…
← prev
page 11 of 33
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 25d ago
↗ source
  • Zymeworks CEO on why the Theravance deal is value for money
    On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...
    Endpoints · 25d ago↗ source
  • BioCryst ends internal discovery programs, will close Alabama research facility
    BioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal di…
    Endpoints · 26d ago↗ source
  • Evommune's lead drug fails in chronic hives, stock sinks
    Evommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin cond…
    Endpoints · 26d ago↗ source
  • Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone disease
    Plus news about Alebund Pharmaceuticals, Regenxbio and Neuphoria Therapeutics. 💸 A SPAC!: Talawar Therapeutics will land on the Nasdaq via a combination with blank-check company JATT II Acquisit…
    Endpoints · 26d ago↗ source
  • Post-Hoc: China deals are pharma’s new tax inversions
    About a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...
    Endpoints · 26d ago↗ source
  • Theravance, after clinical setbacks, agrees to $929M buyout
    <figure><div><img src="https://imgproxy.divecdn.com/adiJN9GDP_sdBKAPLoO1u858OLmoo_2c7bk4eved-BY/g:nowe:919:1/c:1869:1055/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlc…
    BioPharma Dive · 26d ago↗ source
  • Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
    Ipsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...
    Endpoints · 26d ago↗ source
  • 10 clinical trials to watch in the second half of 2026
    <p>The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to…
    BioPharma Dive · 26d ago↗ source
  • FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 28d ago↗ source
  • At BIO, tension over China biotech deal regulation looms
    <figure><div><img src="https://imgproxy.divecdn.com/QMMgdLWmV9_RV75ozi_JOVMqLcnMq3yXkrVCs0nJ7_U/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTgyOTQ2OTI4LmpwZ…
    BioPharma Dive · 28d ago↗ source
  • Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
    <p>Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillio…
    BioPharma Dive · 29d ago↗ source
  • On second try, Acadia drug gets nod from European regulators
    <figure><div><img src="https://imgproxy.divecdn.com/HqB6XqxuaD9NspfVrU6NR4gdT5eCkfyQMHS0wCYOdwk/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjU1OTk4NTE0LmpwZ…
    BioPharma Dive · 29d ago↗ source
  • Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and more
    Welcome back to another edition of Endpoints Weekly! The summer solstice arrives this weekend — the northern hemisphere will reach its maximum tilt toward the sun at 4:24 a.m. Eastern time on Sunda…
    Endpoints · 1mo ago↗ source
  • Endpoints News History: 10 Years, Bootstrap to FT
    Ten years of Endpoints News: no investors, a 50/50 split, profitable from day one. Co-founders Arsalan Arif and John Carroll on how the partnership held.
    Endpoints · 1mo ago↗ source
  • US government launches probe into Germany's plan to pay less for drugs
    Amid Germany's ongoing review of its healthcare spending, the US government has started a trade investigation into the European country's drug pricing system. The investigation, under Section 301…
    Endpoints · 1mo ago↗ source
  • Moderna flu vaccine wins unanimous support from FDA panel
    <figure><div><img src="https://imgproxy.divecdn.com/CkUxnyfQm3Zx49okGV82WTc-N-bBWUdwiWdUqsJeI50/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Nb2Rlcm5hX1Bob3RvXzEuSlBH.webp"/><…
    BioPharma Dive · 1mo ago↗ source
  • FDA vaccine advisors unanimously support Moderna's flu shot
    Every member of a vaccine advisory panel for the FDA voted in favor of Moderna’s flu vaccine, after the product faced roadblocks from previous agency leadership. The Vaccines and Related Biologic…
    Endpoints · 1mo ago↗ source
  • Treasury weighs screening investments in China biotech
    Officials at the Treasury Department are looking at potential restrictions on US investments in China biotech, according to multiple sources familiar with the discussions. At least two sources to…
    Endpoints · 1mo ago↗ source
  • cAMPfield lands $180M to build gut disease drug
    <figure><div><img src="https://imgproxy.divecdn.com/4eoVQHFTAvljHZA3dtwvKrrS1WlgcrV7_wLUFGcZYWw/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjMwMTMxMDIyXzEua…
    BioPharma Dive · 1mo ago↗ source
  • Novo Nordisk expands in China and Czech; Cellares boosts Series D by $50M
    Plus more from Eisai and Siegfried. 🧱 Novo Nordisk's expansions: Novo Nordisk has invested around $380 million to expand its manufacturing facility in Bohumil, Central Bohemia, in the Czech Repu…
    Endpoints · 1mo ago↗ source
  • Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
    <figure><div><img src="https://imgproxy.divecdn.com/Uto2VRn61o7u_sFbw6zPAlwZMdRxZOBYNj0bVh4-oRI/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9nZW5fUGhvdG9fMy5KUEc=.webp"/><…
    BioPharma Dive · 1mo ago↗ source
  • IRA's Medicare out-of-pocket cap increased access to drugs, study finds
    Medication usage, particularly for the most expensive drugs, increased significantly shortly after the Medicare annual out-of-pocket cost cap took effect in January 2025, a study published in JAMA…
    Endpoints · 1mo ago↗ source